Browse our anti-Mitofusin 2 (MFN2) Antibodies

Full name:
anti-Mitofusin 2 Antibodies (MFN2)
On www.antibodies-online.com are 176 Mitofusin 2 (MFN2) Antibodies from 25 different suppliers available. Additionally we are shipping Mitofusin 2 Proteins (10) and Mitofusin 2 Kits (7) and many more products for this protein. A total of 203 Mitofusin 2 products are currently listed.
Synonyms:
anon-WO0125274.3, CG3869, CMT2A, CMT2A2, CPRP1, D630023P19Rik, Dmel\\CG3869, dmfn, Fzo, HSG, marf, Marf-1, mfn, MFN2, mg:cb01g09, si:dkeyp-104h9.2, wu:fb79a11
list all antibodies Gene Name GeneID UniProt
MFN2 9927 O95140
MFN2 170731 Q80U63
MFN2 64476  

Show all species

Show all synonyms

Most Popular Reactivities for anti-Mitofusin 2 (MFN2) Antibodies

Select your species and application

anti-Human Antibodies:

anti-Mouse (Murine) Antibodies:

anti-Rat (Rattus) Antibodies:

All available anti-Mitofusin 2 Antibodies

Go to our pre-filtered search.

Top referenced anti-Mitofusin 2 Antibodies

  1. Human Polyclonal MFN2 Primary Antibody for IF (p), IHC (p) - ABIN682528 : Ku, Ji, Zhang, Li, Sang: PM2.5, SO2 and NO2 co-exposure impairs neurobehavior and induces mitochondrial injuries in the mouse brain. in Chemosphere 2016 (PubMed)
    Show all 2 references for 682528

  2. Human Monoclonal MFN2 Primary Antibody for IHC (p), WB - ABIN2475579 : Minet, Gaster: The dynamic equilibrium between ATP synthesis and ATP consumption is lower in isolated mitochondria from myotubes established from type 2 diabetic subjects compared to lean control. in Biochemical and biophysical research communications 2011 (PubMed)

  3. Human Polyclonal MFN2 Primary Antibody for IHC, IHC (p) - ABIN4334778 : Yang, Yang: Bit-by-bit autophagic removal of parkin-labelled mitochondria. in Nature communications 2013 (PubMed)

  4. Cow (Bovine) Polyclonal MFN2 Primary Antibody for WB - ABIN2775407 : Chung, Cho, Hwang, Kim, Yoo, Kwon, Kim, Sunwoo, Züchner, Choi: Early-onset stroke associated with a mutation in mitofusin 2. in Neurology 2008 (PubMed)

  5. Human Polyclonal MFN2 Primary Antibody for IHC (p), WB - ABIN568087 : Santel, Fuller: Control of mitochondrial morphology by a human mitofusin. in Journal of cell science 2001 (PubMed)

More Antibodies against Mitofusin 2 Interaction Partners

Fruit Fly (Drosophila melanogaster) Mitofusin 2 (MFN2) interaction partners

  1. Clu (show CLU Antibodies) is upstream of and binds to VCP (show vcp Antibodies) in vivo and promotes VCP (show vcp Antibodies)-dependent Marf degradation in vitro Marf accumulates in whole muscle lysates of clu (show CLU Antibodies)-deficient flies and is destabilized upon Clu (show CLU Antibodies) overexpression. Thus, Clu (show CLU Antibodies) is essential for mitochondrial homeostasis and functions in concert with Parkin (show PARK2 Antibodies) and VCP (show vcp Antibodies) for Marf degradation to promote damaged mitochondrial clearance.

  2. lack of ChChd3 (show CHCHD3 Antibodies) leads to inactivation of Hippo activity under normal development, which is also dependent on the transcriptional coactivator Yorkie (Yki (show YAP1 Antibodies)). Furthermore, loss of ChChd3 (show CHCHD3 Antibodies) induces oxidative stress and activates the JNK (show MAPK8 Antibodies) pathway. In addition, depletion of other mitochondrial fusion components, Opa1 (show OPA1 Antibodies) or Marf, inactivates the Hippo pathway as well.

  3. Marf is required for mitochondrial fusion and transport in long axons.

  4. Expression of Mfn2 and endoplasmic reticulum (ER) stress reduction in flies lacking Marf corrected ER shape, attenuating the developmental and motor defects.

  5. Parkin (show PARK2 Antibodies) deficiency and resulting mitophagic disruption produces cardiomyopathy which can be contained by suppressing mitofusin.

  6. mfn2 mutations alter mitochondrial dynamics and induce retinal and cardiac pathology

  7. Data report here that Drosophila Reaper can induce mitochondrial fragmentation by binding to and inhibiting the pro-fusion protein MFN2 and its Drosophila counterpart dMFN/Marf.

  8. MARF and Opa1 (show OPA1 Antibodies) control mitochondrial and cardiac function in Drosophila.

  9. The PINK1 (show PINK1 Antibodies)/Parkin (show PARK2 Antibodies) pathway affects mitochondrial fission/fusion as suggested by previous genetic interaction studies.

  10. Dmfn-mRNA was widely expressed during embryogenesis accumulating in the mesoderm and endoderm during gut (show GUSB Antibodies) development, during oogenesis with transcripts maternally deposited into the early embryo and in the male germ line.

Human Mitofusin 2 (MFN2) interaction partners

  1. PGC-1alpha (show PPARGC1A Antibodies) enhances Mfn2 transcription, but also leads to increased degradation of the Mfn2 protein, a key ubiquitylation target of Parkin (show PARK2 Antibodies) on mitochondria. In vivo, Parkin (show PARK2 Antibodies) has significant protective effects on the survival and function of nigral dopaminergic neurons in which the chronic expression of PGC-1alpha (show PPARGC1A Antibodies) is induced

  2. Exome sequencing identified MFN2 SNVs in two of the individuals. Neuropathy-associated CNV outside of the PMP22 (show PMP22 Antibodies) locus is rare in Charcot-Marie-Tooth (CMT) disease . Nevertheless, there is potential clinical utility in testing for CNVs and exome sequencing in CMT cases negative for the CMT1A (show PMP22 Antibodies) duplication.

  3. Smad2 (show SMAD2 Antibodies) is a key scaffold, allowing RIN1 (show RIN1 Antibodies) to act as a GTP (show AK3 Antibodies) exchange factor for MFN2-GTPase (show RACGAP1 Antibodies) activation to promote mitochondrial ATP synthesis and suppress superoxide production during mitochondrial fusion.

  4. our results suggest that KAP1 (show CDKN3 Antibodies) Ser473 phosphorylation acts through MFN2 reduction to restrict mitochondrial hyperfusion, thereby contributing to cancer cell survival under conditions of sustained metabolic stress

  5. Mfn2 downregulation or the exogenous expression of normal Parkin (show PARK2 Antibodies) restored cytosolic Ca(2 (show CA2 Antibodies)+) transients in fibroblasts from patients with PARK2 (show PARK2 Antibodies) mutations, a catalytically inactive Parkinson's disease (PD)-related Parkin (show PARK2 Antibodies) variant had no effect. Parkin (show PARK2 Antibodies) is directly involved in regulating ER-mitochondria contacts and provide new insight into the role of the loss of Parkin (show PARK2 Antibodies) function in PD development

  6. siRNA knockdown of mitofusin-2 (Mfn2), a protein that is involved in the tethering of endoplasmic reticulum and mitochondria, leads to increased contact between the two organelles.

  7. Taken together, these data suggest that the striking reduction in mitochondria in MNs (show FLNA Antibodies) expressing mutant MFN2 is not the result of impaired biogenesis, but more likely the consequence of enhanced mitophagy.

  8. our findings indicate miR (show MLXIP Antibodies)-106a as an important factor to promote hypertrophic progress and suggest miR (show MLXIP Antibodies)-106a as a new molecular target for the treatment of pathological hypertrophy. The present study also uncovered a novel relationship between miR (show MLXIP Antibodies)-106a and Mfn2, with Mfn2 as a downstream signaling mediator of miR (show MLXIP Antibodies)-106a.

  9. The results of the present study demonstrated that Resveratrol may protect bronchial epithelial cells from cigarette smoke -induced apoptosis in vitro by preventing mitochondrial dysfunction, and MFN2 may be associated with the anti-apoptotic functions of RSV in HBE (show HBe1 Antibodies) cells.

  10. Low MFN2 expression in hepatocellular carcinoma indicated a worse overall survival.

Mouse (Murine) Mitofusin 2 (MFN2) interaction partners

  1. The data of this study suggest that post-translational modification of Mfn2 is associated with its dysregulation during a window of metabolic vulnerability that precedes glaucomatous degeneration.

  2. Study demonstrated that deregulation of mfn2 played a critical role in the mitochondrial disorder during the progression of Alzheimer's disease, and its decreased expression was regulated at least in part by miR (show MLXIP Antibodies)-195. Therefore, upregulation of mfn2 expression by decreasing the level of miR (show MLXIP Antibodies)-195 might be a potential new therapeutic strategy for treatment of Alzheimer's disease.

  3. Mfn2 downregulation or the exogenous expression of normal Parkin (show PARK2 Antibodies) restored cytosolic Ca(2 (show CA2 Antibodies)+) transients in fibroblasts from patients with PARK2 (show PARK2 Antibodies) mutations, a catalytically inactive Parkinson's disease (PD)-related Parkin (show PARK2 Antibodies) variant had no effect. Parkin (show PARK2 Antibodies) is directly involved in regulating ER-mitochondria contacts and provide new insight into the role of the loss of Parkin (show PARK2 Antibodies) function in PD development.

  4. Altogether, these results demonstrate that Mfn2 is a mediator of mitochondria to lipid droplet interactions, influencing lipolytic processes and whole-body energy homeostasis.

  5. we demonstrated that by modulating mitochondrial energy metabolism through Mfn2 and mitochondrial Ca2 (show CA2 Antibodies)+, PPAR-b (show PPARD Antibodies) took an important role in neuronal differentiation induced by flavonoid compound 4a

  6. Furthermore, analysis of muscle Mfn2-deficient mice revealed that aging-induced Mfn2 decrease underlies the age-related alterations in metabolic homeostasis and sarcopenia.

  7. Mice hemizygous for a pathogenic Mfn2 allele exhibit hind limb/foot gait deficits and phenotypic perturbations in nerve and muscle.

  8. We found that mouse embryonic fibroblasts lacking Mfn2 have altered lipid droplet morphology. However, triacylglycerol biosynthesis was not dependent on ER-mitochondrial tethering mediated by mitofusins. Lastly, Mfn2 does not have a role in adipocyte differentiation.

  9. knockdown of Mfn2 in adipo and osteogenesis and the overexpression of a dominant negative form of Drp1 (show CRMP1 Antibodies) during chondrogenesis resulted in a loss of differentiation ability

  10. SIRT1 (show SIRT1 Antibodies) overexpression substantially increased autophagy in wild-type cells, but not in MFN2-deficient cells.

Zebrafish Mitofusin 2 (MFN2) interaction partners

  1. These results highlight the essential role of mitofusin 2 in the motor axon development and demonstrate the potential of zebrafish as a suitable and complementary platform for dissecting pathogenetic mechanisms of MFN2 mutations in vivo.

Cow (Bovine) Mitofusin 2 (MFN2) interaction partners

  1. A highly unusual splicing defect, where an exonic single base exchange leads to the retention of the preceding intron, was identified in MFN2 (show MFN1 Antibodies).

Mitofusin 2 (MFN2) Antigen Profile

Antigen Summary

This gene encodes a mitochondrial membrane protein that participates in mitochondrial fusion and contributes to the maintenance and operation of the mitochondrial network. This protein is involved in the regulation of vascular smooth muscle cell proliferation, and it may play a role in the pathophysiology of obesity. Mutations in this gene cause Charcot-Marie-Tooth disease type 2A2, and hereditary motor and sensory neuropathy VI, which are both disorders of the peripheral nervous system. Defects in this gene have also been associated with early-onset stroke. Two transcript variants encoding the same protein have been identified.

Alternative names and synonyms associated with Mitofusin 2 (MFN2)

  • mitofusin 2 (MFN2) antibody
  • Mitochondrial assembly regulatory factor (Marf) antibody
  • mitofusin 2 (mfn2) antibody
  • mitofusin 2 (Mfn2) antibody
  • mitofusin 2 (LOC100350119) antibody
  • anon-WO0125274.3 antibody
  • CG3869 antibody
  • CMT2A antibody
  • CMT2A2 antibody
  • CPRP1 antibody
  • D630023P19Rik antibody
  • Dmel\\CG3869 antibody
  • dmfn antibody
  • Fzo antibody
  • HSG antibody
  • marf antibody
  • Marf-1 antibody
  • mfn antibody
  • MFN2 antibody
  • mg:cb01g09 antibody
  • si:dkeyp-104h9.2 antibody
  • wu:fb79a11 antibody

Protein level used designations for anti-Mitofusin 2 (MFN2) Antibodies

CG3869-PA , CG3869-PB , CG3869-PC , Marf-PA , Marf-PB , Marf-PC , drosophila mitofusin , mitochondrial assembly regulatory factor , mitofusin , mitofusin 2 , mitofusin-2 , mitofusin-2-like , hyperplasia suppressor , transmembrane GTPase MFN2 , HSG protein , hypertension related protein 1 , hypertension-related protein 1 , hypertension-related protein , mitochondrial transmembrane GTPase FZO1A

GENE ID SPECIES
100055966 Equus caballus
31581 Drosophila melanogaster
457958 Pan troglodytes
549268 Xenopus (Silurana) tropicalis
100172672 Pongo abelii
100186475 Ciona intestinalis
100427191 Macaca mulatta
100470367 Ailuropoda melanoleuca
100599174 Nomascus leucogenys
9927 Homo sapiens
170731 Mus musculus
64476 Rattus norvegicus
567448 Danio rerio
431918 Xenopus laevis
419484 Gallus gallus
487439 Canis lupus familiaris
534574 Bos taurus
100350119 Oryctolagus cuniculus
100512172 Sus scrofa
Selected quality suppliers for anti-Mitofusin 2 (MFN2) Antibodies
Did you look for something else?